Which concomitant medications should be avoided when prescribing Kerendia (finerenone) because they raise its plasma concentrations?

Medications That Raise Kerendia (Finerenone) Blood Levels

Avoid prescribing Kerendia with strong CYP3A4 inhibitors, as this combination is contraindicated and can substantially increase finerenone plasma concentrations, raising the risk of hyperkalemia and other adverse effects. 1

Strong CYP3A4 Inhibitors (Contraindicated)

The following medications are absolutely contraindicated with Kerendia due to their potent inhibition of CYP3A4, which can dramatically increase finerenone levels:

• Antifungals: Ketoconazole, itraconazole 2
• HIV Protease Inhibitors: Ritonavir, nelfinavir, atazanavir 2
  • Note: Ritonavir decreased finerenone clearance by 49.2% in rat studies and increased AUC by 1.95-fold 3
• Macrolide Antibiotics: Clarithromycin, telithromycin 2
• Antidepressants: Nefazodone 2
• Calcium Channel Blockers: Nicardipine 2

The FDA label explicitly states that concomitant use with strong CYP3A4 inhibitors is contraindicated 1.

Moderate CYP3A4 Inhibitors (Avoid or Monitor Closely)

Avoid concomitant use of these medications when possible. If unavoidable, monitor serum potassium closely during initiation or dose adjustment 1:

• Macrolide Antibiotics: Erythromycin 2
  • Increased finerenone AUC by 3.48-fold in clinical studies 4
• Calcium Channel Blockers: Diltiazem, verapamil 2
  • Verapamil increased finerenone AUC by 2.70-fold 4
• Antifungals: Fluconazole 2
  • Decreased finerenone clearance by 50.3% and increased AUC by 1.86-fold in rat studies, with significant elevation in serum potassium 3
• HIV Medications: Saquinavir 2
• Antiarrhythmics: Amiodarone 2

Grapefruit and Grapefruit Juice

Avoid grapefruit or grapefruit juice as they are expected to increase finerenone plasma concentrations through CYP3A4 inhibition 1.

Clinical Context and Mechanism

Finerenone is predominantly metabolized by CYP3A4 (contributing 88-89% of metabolic clearance), with minor involvement of CYP2C8 4. The drug undergoes significant first-pass metabolism in both the gut wall and liver, with an absolute bioavailability of only 43.5% 4. When CYP3A4 is inhibited, finerenone exposure increases substantially, elevating the risk of hyperkalemia—the primary safety concern with this medication.

Common Pitfalls to Avoid

• Don't overlook over-the-counter medications: Many patients take fluconazole or erythromycin without considering them "real" medications
• Check all supplements: Patients may not volunteer information about grapefruit juice consumption
• Remember the contraindication is absolute: Unlike moderate inhibitors where monitoring may suffice, strong CYP3A4 inhibitors are an absolute contraindication per FDA labeling 1
• Consider the clinical scenario: If a patient develops a fungal infection requiring systemic antifungals, you may need to temporarily discontinue Kerendia rather than use a contraindicated combination

Practical Management

When prescribing Kerendia:

1. Review the complete medication list for any CYP3A4 inhibitors
2. Counsel patients to avoid grapefruit products entirely
3. If moderate inhibitors are necessary, increase potassium monitoring frequency (check at 1 month, then every 4 months per guidelines) 5
4. Consider alternative antimicrobials when treating infections (e.g., azithromycin instead of clarithromycin)
5. Find alternative antifungals when possible (e.g., topical agents for superficial infections)